Mayo Clinic researchers say they have discovered that ovarian cancer cells can quickly activate a survival response after treatment with PARP inhibitors.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...

Particle therapy, including proton and carbon ion radiotherapy, represents a major advancement in cancer treatment due to its ...